Educational Session |
09:00~10:10 |
1. Innovative Treatment |
Room A |
1) Innovative Treatment in Urologic Malignancies |
Jae Lyun Lee (Univ. of Ulsan College of Medicine, Asan Medical Center) |
2) Innovative Treatment in Hematologic Malignancies |
Chul Won Jung (Sungkyunkwan University School of Medicine, Samsung Medical Center) |
3) Tailored Management of Metastatic Breast Cancer Based on Molecular Subtypes |
Seock Ah Im (Seoul National University College of Medicine) |
2. Short Course Stereotactic Body Radiotherapy (SBRT) for Oligometastases |
Room B |
1) SBRT Role for Oligometastases : Expected Survival Benefit |
Mi-Sook Kim (Korea Institute Radiological & Medical Sciences) |
2) Liver & Lung Oligometastases : SBRT vs Surgery |
Woo Chul Kim (Inha University Hospital) |
3) Bone Oligometastases : Role of SBRT |
Jin Ho Kim (Seoul National University Hospital Integrated Cancer Care Center) |
3. Clinical Trials in Surgical Oncology |
Room C |
1) How to Design Clinical Trial in Surgical Oncology? |
Young-Woo Kim (National Cancer Center) |
2) How to Standardize and Overcome Variation of Surgical Treatment? |
Jin-Young Jang (Seoul National University College of Medicine) |
3) Role of the Surgeon in an Oncology Trial |
Gyu Seog Choi (Kyungpook National University Medical Center) |
|
Plenary Lecture 3 |
10:30~11:10, Room A ~ C |
Linking "Novel Target Discovery" to Clinic and Pharma |
Sung Hoon Kim, Ph.D. (Biopharmaceutical Sciences College of Pharmacy, Seoul National University) |
|
Plenary Lecture 4 |
11:10~12:00, Room A ~ C |
Novel Therapeutic Strategies for Cancer Stem Cells |
Hideyuki Saya, M.D. (School of Medicine, Keio University, Japan) |
|
Symposium 5 |
13:50~15:30, Room A |
Successful Cooperation between Pharmaceutical & Clinical Researchers in Oncology Drug R&D |
Joint Symposium (Korean Cancer Association and National OncoVenture) |
1) Clinicians Role in the Development of New Anticancer Agents |
Jung-Yong Kim (National OncoVenture) |
2) Innovative Target Discovery for Therapeutic Antibody |
Youngwoo Park (Korea Research Institute of Bioscience & Biotechnology) |
3) Open Innovation and Clinical Development of a Novel Pan-Her Inhibitor Poziotinib |
Jee Woong Son (Vice President of Hanmi Pharm) |
4) Best Development of Cancer Drug by Translating Biologic Discovery into Clinical Trials |
Ji-Youn Han (National Cancer Center) |
|
Symposium 6 |
15:50~17:30, Room A |
Issues in Conducting Clinical Trials between the Cooperative Groups |
1) Hurdles and Issues for Conducting Collabolative Clinical Trials with EORTC |
Hwan Jung Yun (Chungnam National University School of Medicine) |
2) Experiences of KGOG in Conducting Clinical Trials of GOG and GCIG |
Jae Hoon Kim (Yonsei University College of Medicine) |
3) KCSG Experience in International Collaboration - Challenges and Opportunities |
Jee Hyun Kim (Seoul National University Bundang Hospital) |
4) Collaboration between KROG and RTOG |
Kwan Ho Cho (National Cancer Center) |
|
Symposium 7 |
13:50~15:30, Room C |
Molecular Imaging for Theragnostics |
1) Molecular Imaging for Surgical Resection of Cancer |
Hyun Koo Kim (Korea University College of Medicine) |
2) Programming of Bacteria for Cancer Theragnostics |
Jung-Joon Min (Chonnam National University Medical School) |
3) Radio-theragnostics for Tumor Angiogenesis in a Tumor-bearing Mouse Model and a Pilot Study in Human Patients |
Byung Chul Lee (Seoul National University Bundang Hospital) |
4) Molecular Imaging for Personalized Theragnostics |
Mei Tian, M.D., Ph.D. (Zhejiang University School of Medicine, China) |
|
Symposium 8 |
15:50~17:30, Room C |
Cancer Metabolism |
1) Targeting Arginine-dependent Cancers with Pegylated Arginine Deiminase |
Peter Szlosarek, Ph.D. (Barts Cancer Institute - a Cancer Research UK Centre of Excellence, Queen Mary, University of London, UK) |
2) Metabolic Remodelling in Papillary Thyroid Cancer |
Minho Shong (Chungnam National University School of Medicine) |
3) Diagnosis of Cancer Using Metabolomics Method |
Seung Hong Choi (Seoul National University College of Medicine) |
4) Effect of Metformin for Breast Cancer |
Wonshik Han (Seoul National University College of Medicine) |
|
Symposium 9 |
13:50~15:30, Room E |
Current Standard and Future Perspectives in Gynecologic Cancer |
Joint Symposium (Korean Cancer Association and Korean Society of Gynecologic Oncology) |
1) Cervical Cancer Screening Paradigm Shift is Possible? From Cytology to HPV Molecular Diagnostics |
Jae-Kwan Lee (Korea University Guro Hospital) |
2) Improving Ovarian Cancer Screening with Novel Biomarker Algorithm |
Yong Man Kim (Univ. of Ulsan College of Medicine, Asan Medical Center) |
3) Current Clinical Evidence & Future Direction of Molecular Target Therapy in Epithelial Ovarian Cancer |
Jae Weon Kim (Seoul National University College of Medicine) |
4) Retroperitoneal Lymphadnectomy Can be Safely Omitted in Selected Early Stage Endometrial Cancer |
Sokbom Kang (National Cancer Center) |
|
Symposium 10 |
15:50~17:30, Room E |
Research, Clinical Practice and Policy for Cancer Survivorship |
1) Updates in Cancer Survivorship Research |
Dae Ho Lee (Univ. of Ulsan College of Medicine, Asan Medical Center) |
2) Updates in Cancer Survivorship Clinical Practice |
Myong Cheol Lim (National Cancer Center) |
3) Research for Cancer Survivorship Health Management in Oncology Nursing Priorities for Research and Development in Oncology Nursing Service |
Eui Geum Oh (College of Nursing, Yonsei University) |
4) Framework for Translating Cancer Survivorship Research into Clinical Practice and Policy |
Young Ho Yun (Seoul National University Hospital Integrated Cancer Care Center) |
|
Luncheon Symposium 2 |
12:00~13:00, Room A ~ C |
Anti-angiogenic Drugs for Colorectal Cancer: Exploring New Possibilities |
Napoleone Ferrara, M.D. (Moores Cancer Center, University of California, USA) |